What is LENSAR?
Headquartered in Orlando, Florida, LENSAR, Inc. operates at the intersection of advanced robotics and ophthalmology. The company specializes in the development of high-precision laser systems designed to enhance the safety and clinical outcomes of cataract surgery. By prioritizing a patient-centered approach, LENSAR has established itself as a critical player in the medical device landscape, providing surgeons with the tools necessary to perform complex refractive procedures with unprecedented accuracy. Their market position is bolstered by a commitment to innovation and a robust intellectual property framework that supports their technological advancements.
How much funding has LENSAR raised?
LENSAR has raised a total of $154.4M across 6 funding rounds:
Other Financing Round
$24M
Multiple Rounds
$114.4M
Unspecified
$16M
Other Financing Round (2012): $24M with participation from Aisling Capital and Florida Growth Fund
Unspecified (2013): $17.4M, investors not publicly disclosed
Private Equity (2013): $27M supported by PDL Biopharma, Florida Opportunity Fund, Florida Growth Fund, and Aisling Capital
Debt (2013): $60M featuring PDL BioPharma, Inc.
Private Equity (2013): $10M, investors not publicly disclosed
Unspecified (2015): $16M with participation from Undisclosed
Key Investors in LENSAR
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies.
Florida Growth Fund
Florida Growth Fund is a firm operating in the investment banking industry, focused on fostering economic development and innovation within the state of Florida.
PDL BioPharma, Inc.
PDL BioPharma manages a diverse portfolio of patents and royalty assets, providing strategic financial support to biotechnology and pharmaceutical enterprises.
What's next for LENSAR?
Following this major strategic investment, LENSAR is well-positioned to accelerate its commercialization efforts and expand its footprint in the global refractive surgery market. The company's focus will likely shift toward scaling its manufacturing capabilities and deepening its penetration into clinical settings that demand high-precision surgical solutions. By leveraging its existing technological infrastructure and the support of its institutional partners, LENSAR is poised to continue its growth trajectory, potentially exploring new applications for its robotic platforms to address broader ophthalmic needs and maintain its competitive edge in the evolving healthcare technology ecosystem.
See full LENSAR company page
